StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/307% above fair value
$63.34−1.54 (-2.37%)

Close on Nov 20, 2026Market cap $9.70BP/E 23.1Yield –

TG Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

TG Therapeutics's net income for the twelve months ending Jun 30, 2026 was $441.49M, up 630.2% year over year. For fiscal 2025 it was $447.18M, up 1812.4% from the year before. The highest annual figure on record is $447.18M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$447.18M+1812.4%
FY2024Dec 31, 2024$23.38M+84.5%
FY2023Dec 31, 2023$12.67M–
FY2022Dec 31, 2022-$223.81M–
FY2021Dec 31, 2021-$348.10M–
FY2013Dec 31, 2013-$20.48M–
FY2012Dec 31, 2012-$18.07M–
FY2011Dec 31, 2011-$853.07K-236.8%
FY2010Dec 31, 2010$623.65K–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.78M-72.4%
Q1 FY2026Mar 31, 2026$19.78M+290.8%
Q4 FY2025Dec 31, 2025$23.04M-1.3%
Q3 FY2025Sep 30, 2025$390.90M+9974.6%
Q2 FY2025Jun 30, 2025$28.19M+309.8%
Q1 FY2025Mar 31, 2025$5.06M–
Q4 FY2024Dec 31, 2024$23.33M–
Q3 FY2024Sep 30, 2024$3.88M-96.6%
Q2 FY2024Jun 30, 2024$6.88M–
Q1 FY2024Mar 31, 2024-$10.71M–
Q4 FY2023Dec 31, 2023-$14.42M–
Q3 FY2023Sep 30, 2023$113.93M–
Q2 FY2023Jun 30, 2023-$47.61M–
Q1 FY2023Mar 31, 2023-$39.23M–
Q4 FY2022Dec 31, 2022-$78.47M–
Q3 FY2022Sep 30, 2022-$35.82M–
Q2 FY2022Jun 30, 2022-$40.51M–
Q1 FY2022Mar 31, 2022-$69.01M–
Q4 FY2019Dec 31, 2019-$39.57M–
Q3 FY2019Sep 30, 2019-$61.93M–
Q2 FY2019Jun 30, 2019-$36.21M–
Q1 FY2019Mar 31, 2019-$35.16M–
Q4 FY2018Dec 31, 2018-$53.86M–
Q3 FY2018Sep 30, 2018-$33.95M–
Q2 FY2018Jun 30, 2018-$44.14M–
Q1 FY2018Mar 31, 2018-$41.53M–
Q4 FY2017Dec 31, 2017-$30.86M–
Q3 FY2017Sep 30, 2017-$31.54M–
Q2 FY2017Jun 30, 2017-$28.35M–
Q1 FY2017Mar 31, 2017-$27.73M–
Q4 FY2016Dec 31, 2016-$23.67M–
Q3 FY2016Sep 30, 2016-$24.83M–

More TG Therapeutics figures

See a number that looks wrong?